Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
IPH 1101 in combination with rituximab enters the second part of the Phase I/II trial in fNHL
July 16, 2008
Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.
| Download Area |
|---|
| PR in english |
| CP en français |